Revance Therapeutics Inc. (RVNC) had a good day on the market for Monday December 02 as shares jumped 11.87% to close at $20.03. About 1.54 million shares traded hands on 11,711 trades for the day, compared with an average daily volume of n/a shares out of a total float of 45.11 million. After opening the trading day at $18.70, shares of Revance Therapeutics Inc. stayed within a range of $20.54 to $18.41.
With today’s gains, Revance Therapeutics Inc. now has a market cap of $903.29 million. Shares of Revance Therapeutics Inc. have been trading within a range of $24.99 and $9.88 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Revance Therapeutics Inc is a clinical-stage biotechnology company. It is focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company’s proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. The company is pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. It holds rights for all indications of RT002 injectable and RT001 topical, and the pharmaceutical uses of its proprietary peptide technology.
Revance Therapeutics Inc. is based out of Newark, CA and has some 170 employees. Its CEO is Mark J. Foley.
